Oruka Therapeutics (ORKA) reports director Christopher Martin option grant

Rhea-AI Filing Summary

Oruka Therapeutics, Inc. director Christopher Martin reported receiving stock options to purchase 35,000 shares of the company’s common stock at an exercise price of $30.21 per share on December 11, 2025.

The options expire on December 10, 2035 and vest in equal monthly installments, with 1/36 of the underlying shares vesting each month starting December 11, 2025. After this grant, he beneficially owns options for 35,000 shares, held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Martin Christopher Nathan

(Last) (First) (Middle)

C/O ORUKA THERAPEUTICS, INC.

855 OAK GROVE AVE., SUITE 100

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Oruka Therapeutics, Inc. [ ORKA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$30.21	12/11/2025		A		35,000		(1)	12/10/2035	Common Stock	35,000	$0	35,000	D

Explanation of Responses:

1. The option vests as to 1/36 of the underlying shares monthly from December 11, 2025.

	/s/ Paul Quinlan, as attorney-in-fact for Christopher Martin	12/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Oruka Therapeutics (ORKA) report for Christopher Martin?

Director Christopher Martin reported receiving a stock option covering 35,000 shares of Oruka Therapeutics common stock on December 11, 2025.

How many Oruka Therapeutics (ORKA) stock options were granted and at what exercise price?

The reported grant was a stock option (right to buy) for 35,000 derivative securities, each for one share of common stock, with an exercise price of $30.21 per share.

When do Christopher Martin’s Oruka Therapeutics (ORKA) options vest?

According to the footnote, the option vests as to 1/36 of the underlying shares monthly starting from December 11, 2025.

When do these Oruka Therapeutics (ORKA) stock options expire?

The stock options have an expiration date of December 10, 2035, as shown in the derivative securities table.

How many derivative securities does Christopher Martin beneficially own after this transaction?

Following the reported transaction, Christopher Martin beneficially owns 35,000 derivative securities (stock options), held in direct ownership.

What is Christopher Martin’s relationship to Oruka Therapeutics (ORKA)?

The form identifies Christopher Martin as a Director of Oruka Therapeutics, Inc., and the filing is marked as Form filed by One Reporting Person.